Dr Kola Tytler MBBS CertHE MBA MRCGPClinical Lead • iatroX
Indications for non-invasive prenatal testing (NIPT) or cell-free DNA (cfDNA) testing are generally established in the first trimester of pregnancy, up to 13 completed weeks. This timing aligns with the period when early pregnancy assessments and screening for chromosomal conditions are typically performed, including the first trimester ultrasound scan to estimate gestational age and determine chorionicity in multiple pregnancies. Offering NIPT during this early stage allows for timely risk assessment and informed decision-making regarding chromosomal abnormalities.